**Position on Biodiversity**

Lundbeck does not operate in areas of high biodiversity value. Nor do we source natural resources from suppliers operating under a biodiversity policy or certification scheme e.g. The Forest Stewardship Council (FSC). However, Lundbeck takes biodiversity seriously and appropriate actions are taken to eliminate, reduce or mitigate potential impacts arising from activities or processes at all our sites and facilities.

Our environmental footprint is dominated by the use of raw materials and resources (water and energy), the generation of waste, wastewater and airborne emissions. We seek to reduce our environmental impact by performing risk assessments, optimize processes and use the least harmful substances in our production.

Chemical residues may cause a potential risk to the aquatic ecosystem and we acknowledge the potential environmental risk posed by medicinal residues from production and patients. Lundbeck takes the matter seriously and we monitor the environmental effects of the active pharmaceutical ingredients in our new medicinal products. By establishing and implementing the necessary biological and physical/chemical studies, we assess the effect on biodiversity to various aquatic organisms as an integral part of our Environmental Risk Assessment process. The knowledge gained is applied to the design and manufacturing process resulting in the least possible environmental impact.

Lundbeck is not considered a big contributor of micro plastics to the environment. The uses of intentionally added micro plastics in our pharmaceuticals (tablets) are limited to the use of microcrystalline cellulose. This solid water insoluble polymer fall under the broadly defined category “micro plastics”. We closely follow the growing global awareness on the matter and proactively collaborate with key stakeholders, like ECHA, to gain additional knowledge on the matter. As for macro plastics, Lundbeck has worked dedicated for numerous years to segregate (both hard and soft) plastic waste for reuse/recycling, as part of our corporate approach on circular economy.

Control invasive species is relevant to Lundbeck, as we use low-risk genetically-modified animals and organisms (GMO) in our research and development of new pharmaceuticals. By high ethical standards of animal welfare, we work according to strict legislation, systems and routines to make sure all organisms are kept enclosed in designated laboratories and ensure no GMO-organisms are introduced to our wildlife by accident.

Our future key challenges and opportunities at Lundbeck with regard to Biodiversity include:

- Supporting initiatives to improve data quality and minimising the presence and effects of pharmaceuticals in the environment. E.g. by participating in European and national industry networks to exchange experience.
- Proactively follow national and global focus on micro plastics in the environment, to act and optimize our behaviour accordingly.
- Continually minimising the use of raw materials and the generation of waste by optimizing our processes and recovering solvents.
- Reducing the presence of solvents and pharmaceuticals in wastewater and air emissions by substituting harmful substances and promoting clean emissions from production.
- Developing and maintaining our environmental principles in the Lundbeck Supplier Standards e.g. by auditing our suppliers in environmental issues.
- Keeping an open and honest dialogue with our stakeholders e.g. by reporting our HSE performance and actions to UN Global Compact, FTSE4GOOD and Carbon Disclosure Project.

In our UN Global Compact Progress report on [www.Lundbeck.com](http://www.Lundbeck.com) you can read more about our activities and performance.